VKTX
Viking Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.79
−7.79%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$27.61
From 52W high−38.78%
Volume4.80M
Market cap$3.29B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 5, 2026
Open
$27.61
From 52W high
−38.78%
Volume
4.80M
Market cap
$3.29B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.1x
P/E (TTM)
—
RSI (14)
43.9
MomentumView details →
1D Return
−7.79%
YTD Return
−26.78%
SummaryUpdated Sep 1, 2026
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing novel therapies for metabolic and endocrine disorders. Viking has emerged as a significant player in the obesity and metabolic disease treatment space, with multiple drug candidates in various stages of clinical development targeting conditions such as obesity, non-alcoholic steatohepatitis (NASH), and rare metabolic disorders.
Similar companies
Latest newsMore news →
Viking Therapeutics, Inc. reported a wider third-quarter loss as rising clinical expenses weighed on results.7d agoViking Therapeutics, Inc. reported financial results for the third quarter and nine months ended September 30, 2026, and reported a quarter-end cash position of $960 million.8d agoViking Therapeutics, Inc. announced positive top-line results from its VK2735 maintenance dosing study and initiated Part 2 of the study.8d ago